When botulinum toxin is used for plantar fasciitis, the goal is to alleviate the problem with a single treatment; when this goal is achieved (and there is no retreatment), the “duration of effect” is indefinite rather than a well-defined value. Hence, it would be counter-intuitive for duration of effect to be a secondary endpoint in the PF trial.
I’m not sure what you’re asking. There is no Botox-comparator arm in the PF trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.